JP2013507970A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507970A5
JP2013507970A5 JP2012535411A JP2012535411A JP2013507970A5 JP 2013507970 A5 JP2013507970 A5 JP 2013507970A5 JP 2012535411 A JP2012535411 A JP 2012535411A JP 2012535411 A JP2012535411 A JP 2012535411A JP 2013507970 A5 JP2013507970 A5 JP 2013507970A5
Authority
JP
Japan
Prior art keywords
mucosal
cells
nucleic acid
antigen
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012535411A
Other languages
English (en)
Japanese (ja)
Other versions
JP5955771B2 (ja
JP2013507970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/053733 external-priority patent/WO2011066048A1/en
Publication of JP2013507970A publication Critical patent/JP2013507970A/ja
Publication of JP2013507970A5 publication Critical patent/JP2013507970A5/ja
Application granted granted Critical
Publication of JP5955771B2 publication Critical patent/JP5955771B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012535411A 2009-10-22 2010-10-22 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法 Active JP5955771B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25411909P 2009-10-22 2009-10-22
US61/254,119 2009-10-22
PCT/US2010/053733 WO2011066048A1 (en) 2009-10-22 2010-10-22 Cell-based anti-cancer compositions and methods of making and using the same

Publications (3)

Publication Number Publication Date
JP2013507970A JP2013507970A (ja) 2013-03-07
JP2013507970A5 true JP2013507970A5 (https=) 2013-12-12
JP5955771B2 JP5955771B2 (ja) 2016-07-20

Family

ID=44066847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535411A Active JP5955771B2 (ja) 2009-10-22 2010-10-22 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法

Country Status (4)

Country Link
US (2) US20120251509A1 (https=)
EP (2) EP3444333A1 (https=)
JP (1) JP5955771B2 (https=)
WO (1) WO2011066048A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
SG10201407757XA (en) 2009-10-23 2015-01-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
AU2013251312B2 (en) 2012-04-27 2018-03-22 Takeda Pharmaceutical Company Limited Anti-GCC antibody molecules and use of same to test for susceptibility to GCC-targeted therapy
US9393268B2 (en) * 2013-03-15 2016-07-19 Thomas Jefferson University Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
WO2015051304A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarkers and their use in treatment of cancer
IL302560B2 (en) * 2015-10-13 2025-08-01 Hope City Chimeric antigen receptors containing a chlorotoxin domain
JP2018042481A (ja) * 2016-09-13 2018-03-22 テラ株式会社 抗原特異的t細胞含有組成物及びその製造方法
BR112019011065A2 (pt) 2016-12-03 2019-10-01 Juno Therapeutics Inc métodos para determinação da dosagem de células t car
KR20190098747A (ko) 2016-12-05 2019-08-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료법을 위한 조작된 세포의 제조방법
WO2019089511A1 (en) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
CA3093705A1 (en) * 2018-03-16 2019-09-19 Thomas Jefferson University Anti-gucy2c chimeric antigen receptor compositions and methods
US20250243272A1 (en) * 2019-11-08 2025-07-31 Good T Cells, Inc. Epitope of regulatory t cell surface antigen, and antibody specifically binding thereto

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US4022878A (en) 1972-05-15 1977-05-10 Biological Developments, Inc. Methods and compounds for producing specific antibodies
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4329281A (en) 1978-06-05 1982-05-11 Hoffmann-La Roche Inc. Hapten compositions
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
JPS62162963A (ja) 1986-01-10 1987-07-18 Sadao Shiosaka 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5204243A (en) 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5668267A (en) * 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
DE69723580T2 (de) 1996-05-03 2004-06-03 Thomas Jefferson University Impfstoff gegen metastasierenden kolorektalkrebs.
US5780447A (en) 1996-06-14 1998-07-14 St. Jude Children's Research Hospital Recombinant adeno-associated viral vectors
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US20020018783A1 (en) * 1997-03-20 2002-02-14 Michel Sadelain Fusion proteins of a single chain antibody and cd28 and uses thereof
CA2404431C (en) 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
CA2417866A1 (en) * 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2005049073A2 (en) * 2003-11-19 2005-06-02 Survac Aps Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
EP1994406A1 (en) * 2006-03-16 2008-11-26 Leiden University Medical Center Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
US9001515B2 (en) 2012-04-20 2015-04-07 Cisco Technology, Inc. Universal pull tab release for modules including fiber optic and cable accessibilities
US9939808B2 (en) 2014-03-06 2018-04-10 Texas Instruments Incorporated Monitor data attachment to product lots for batch processes

Similar Documents

Publication Publication Date Title
JP2013507970A5 (https=)
CN106243219B (zh) 一种猪源性抗猪流行性腹泻病毒的单链抗体及其制备方法
JP2012143232A5 (https=)
JP2007197439A5 (https=)
JP2017114866A5 (https=)
FI3527070T3 (fi) Humanisoituja kevytketjuhiiriä
JP2014110814A5 (https=)
JP2016512034A5 (https=)
CN104004095A (zh) 一种cd7纳米抗体、其编码序列及应用
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
HRP20161548T1 (hr) Protutijela za il-25
JP2017538412A5 (https=)
Yisimayi et al. Repeated Omicron infection alleviates SARS-CoV-2 immune imprinting
JP2015508056A5 (https=)
CN104211785B (zh) 鸭坦布苏病毒e蛋白第三结构域重组蛋白及其应用
MX2022014243A (es) Proteina de union al antigeno st2.
EA202191658A1 (ru) Антитела против фактора c2b комплемента человека и способы применения
MXPA06008217A (es) Vacunas con subunidad de lawsonia intracellularis.
Park et al. Broadly neutralizing antibodies targeting pandemic GII. 4 variants or seven GII genotypes of human norovirus
EP3077508A2 (en) Methods of utilizing recombination for the identification of binding moieties
JPWO2021075545A5 (https=)
WO2020057742A1 (en) Vaccine and antibody against clostidioides difficile toxin
CN103467599B (zh) 双峰驼源抗猪瘟兔化弱毒疫苗株e2抗原重链抗体vhh和用途
Fischer et al. Isolation of genetically diverse influenza antibodies highlights the role of IG germline gene variation and informs the design of population-comprehensive vaccine strategies
CN106632670B (zh) 一种猪源性抗猪传染性胃肠炎病毒的单链抗体及其制备方法